| Literature DB >> 25386217 |
Fahmida Alam1, Md Asiful Islam1, Siew Hua Gan1, Md Ibrahim Khalil2.
Abstract
Diabetic wounds are unlike typical wounds in that they are slower to heal, making treatment with conventional topical medications an uphill process. Among several different alternative therapies, honey is an effective choice because it provides comparatively rapid wound healing. Although honey has been used as an alternative medicine for wound healing since ancient times, the application of honey to diabetic wounds has only recently been revived. Because honey has some unique natural features as a wound healer, it works even more effectively on diabetic wounds than on normal wounds. In addition, honey is known as an "all in one" remedy for diabetic wound healing because it can combat many microorganisms that are involved in the wound process and because it possesses antioxidant activity and controls inflammation. In this review, the potential role of honey's antibacterial activity on diabetic wound-related microorganisms and honey's clinical effectiveness in treating diabetic wounds based on the most recent studies is described. Additionally, ways in which honey can be used as a safer, faster, and effective healing agent for diabetic wounds in comparison with other synthetic medications in terms of microbial resistance and treatment costs are also described to support its traditional claims.Entities:
Year: 2014 PMID: 25386217 PMCID: PMC4216698 DOI: 10.1155/2014/169130
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Successful clinical evidence of using honey on diabetic wounds (2005–2014).
| Number | Age of diabetic patient (years) | Sex | Clinical complications | Type of honey | Course of treatment | Resolution time | Reference (country, year) |
|---|---|---|---|---|---|---|---|
| 1 | 52 | Male | Postoperative (amputation) right foot ulcer | Natural honey | Once daily | 4 weeks | [ |
|
| |||||||
| 2 | Male: 54.6 ± 12.7 (Mean ± SD) | Male | Wagner grades II, III, and IV diabetic foot ulcers Diabetic foot ulcers | Manuka honey | Once daily | 11 days |
[ |
| Female: 58.7 ± 13.4 (Mean ± SD) | Female | ||||||
|
| |||||||
| 3 | 55 | Male | Diabetic foot ulcer | Natural honey | Once daily | 4 weeks | [ |
|
| |||||||
| 4 | 48 | Male | Postoperative (amputation) right foot wound | Honey-based gel | Twice weekly | 2 months | [ |
|
| |||||||
| 5 | 87 | Female | Postoperative (amputation) left foot wound | Honey-based gel | Once daily | 4 weeks |
|
|
| |||||||
| 6 | 52.3 (Mean) ( | 56.7% Male | Diabetic wound | Pure raw untreated commercial honey | Once daily | 2.3 weeks (mean) | [ |
|
| |||||||
| 7 | 46 (Mean) ( | 8 Male | Wagner types I, II, III, and IV | Natural honey | Initially once a day | Fast excellent recovery | [ |
|
| |||||||
| 8 | 52.1 (Mean) ( | 15 Male | Wagner grade II diabetic foot ulcers | Commercial honey | Once daily | 14.4 days |
[ |
| 15 Female | |||||||
|
| |||||||
| 9 | 65 | Male | Diabetic foot wound | A paste made of honey, propolis, and myrrh | Once daily | 4 weeks | [ |
|
| |||||||
| 10 | 79 | Male | Diabetic foot ulcer | Supermarket honey | Once daily | 6 months | [ |
|
| |||||||
| 11 | 62 | Male | Diabetic foot ulcer | Manuka honey | Twice weekly | 54% reduced by 4 weeks | [ |
The effectiveness of honey against microorganisms that are usually found in diabetic wounds.
| Microorganisms found in diabetic wounds and references | Microorganisms found to have sensitivity to honey | Honey origin and type with reference |
|---|---|---|
|
| ||
|
|
| Nigeria, unprocessed raw honey [ |
| New Zealand, Pasture and Manuka honey [ | ||
| United Arab Emirates, Manuka honey [ | ||
| Saudi Arabia, commercial honey [ | ||
| USA, commercial honey [ | ||
| MRSA ATCC 43300, | Rio San Pedro Ltd. Chile, Ulmo 90 honey [ | |
|
| Australia, Medihoney [ | |
|
|
| Nigeria, unprocessed raw honey [ |
| United Arab Emirates, Manuka honey [ | ||
|
|
| India, raw local honey [ |
|
|
| Egypt, various monofloral honeys [ |
|
| ||
|
| ||
|
|
| Nigeria, unprocessed raw honey [ |
| United Arab Emirates, Manuka honey [ | ||
| India, raw and processed local honey [ | ||
| Rio San Pedro Ltd. Chile, Ulmo 90 honey [ | ||
| Australia, Medihoney [ | ||
| Saudi Arabia, commercial honey [ | ||
|
|
| Nigeria, unprocessed raw honey [ |
|
|
| Nigeria, unprocessed raw honey [ |
| Australia, Medihoney [ | ||
| Turkey; Anzer, Bayburt and Chest nut honey [ | ||
|
|
| Ethiopia, Raw honey [ |
| India, raw and processed local honey [ | ||
| Rio San Pedro Ltd. Chile, Ulmo 90 honey [ | ||
| India, local marketed honey [ | ||
| Australia, Medihoney [ | ||
| Saudi Arabia, commercial honey [ | ||
|
| ||
|
| ||
|
|
| Nigeria, unprocessed raw honey [ |
|
|
| Nigeria, unprocessed raw honey [ |
|
|
| Thailand, commercial honey [ |
|
|
| Nigeria, unprocessed raw honey [ |
| Australia, Medihoney [ | ||
|
|
| Brazil, propolis [ |
|
|
| New Zealand, Manuka honey [ |
|
| ||
|
| ||
|
|
| Iran, local honey [ |
|
|
| Nigeria, unprocessed raw honey [ |
| United Arab Emirates, Manuka honey [ | ||
| Iran, local honey [ | ||
Limitations of common topical agents used in wound healing.
| Name | Side effects and limitation | References |
|---|---|---|
| Silver nitrate | (1) Skin discoloration and irritation | [ |
| (2) Toxicity to epithelium | [ | |
| (3) The bacterial reduction of nitrate to nitrite may lead to methemoglobinemia with the use of this topical agent | [ | |
|
| ||
| Silver | Absorption, systemic distribution, and excretion in urine | [ |
|
| ||
| Polyhexamethylene biguanide | Ineffective when there is a measurable degree of wound fluid suppuration because of its short residence times on the wound site | [ |
|
| ||
| Proflavine | Induces mutations in bacterial and cell cultures | [ |
|
| ||
| Povidone iodine | (1) Short residence times on the wound site | [ |
| (2) Can cause severe metabolic acidosis | [ | |
| (3) Cytotoxicity against leukocytes, fibroblasts, and keratinocytes | [ | |
| (4) Polymorphonuclear leukocytes are inhibited by this topical agent | [ | |
| (5) Povidone iodine has also reportedly been inactivated by wound exudates | [ | |
| (6) May “harden” wound eschar rather than softening it, thus increasing the difficulty and discomfort of wound debridement | [ | |
| (7) Should not be used during pregnancy, on a newborn, on small children, or on patients with suspected or known thyroid disease | [ | |
|
| ||
| Hydrogen peroxide | (1) Formation of air emboli in wounds | [ |
| (2) The mechanical cleansing effect of hydrogen peroxide, often attributed to its “fizzing” (which is caused by its decomposition into oxygen and water when it comes in contact with blood and tissue fluids), is questionable | [ | |
| (3) Is toxic to fibroblasts | [ | |
| (4) Impairs the microcirculation of wounds | [ | |
| (5) Limited bactericidal effectiveness | [ | |
|
| ||
| Diluted iodine solutions (iodine solution USP [United States Pharmacopeia] [2% iodine, 2.5% sodium iodide] and Iodine tincture USP [2% iodine, 2.5% sodium iodide, 50% alcohol]) | May irritate tissue, stain the skin, and cause sensitization | [ |
|
| ||
| Povidone iodine | Contact dermatitis has been reported with prolonged uninjured skin exposure to ointment | [ |
|
| ||
| Chlorhexidine | (1) Associated with few adverse effects on healing | [ |
| (2) MRSA resistance has been found | [ | |
|
| ||
| Chlorhexidine gluconate solution | Prolonged, repeated use may lead to contact dermatitis | [ |
|
| ||
| Acetic acid 0.5%. | (1) Acetic acid has demonstrated toxicity to fibroblasts in culture | [ |
| (2) Reduced epithelial cell proliferation in culture | [ | |
| (3) Delayed healing of cultured epithelial autografts has been reported at 0.25% strength | [ | |
| (4) Acetic acid has been shown to reduce PMN function | [ | |
|
| ||
| Sodium hypochlorite (Dakin's solution) | (1) Has caused toxicity to fibroblasts in culture | [ |
| (2) Toxicity to keratinocytes in culture | [ | |
| (3) Polymorphonuclear leukocyte viability is inhibited | [ | |
| (4) Acidosis may result from continuous use over large-area wounds. This solution may also cause pain | [ | |
|
| ||
|
| ||
| Silver sulfadiazine cream | (1) Not effective for highly exuding wounds; rapidly absorbs fluid, loses its rheological characteristics, and becomes mobile as it remains on wounds for longer periods of time | [ |
| (2) 3–5% incidence of reversible leucopenia | [ | |
| (3) There is evidence that silver sulfadiazine is toxic to human keratinocytes and fibroblasts in vitro | [ | |
| (4) Should be avoided during pregnancy, on premature infants or on infants younger than 2 months of age | [ | |
|
| ||
| Silver nitrate ointment | Same problems as silver sulfadiazine cream | [ |
|
| ||
| Neosporin | Hypersensitivity is more common because of the presence of neomycin in the ointment | [ |
|
| ||
| Nitrofurazone 0.2% compound | (1) Bacteria may develop mild resistance with prolonged use | [ |
| (2) Detrimental effects on the growth and migration of keratinocytes in culture | [ | |
| (3) The development of the usual symptoms of contact dermatitis (rash, local edema, and pruritus) | [ | |
|
| ||
| Gentamicin 0.1% cream | (1) Can inhibit PMN activity | [ |
| (2) Skin hypersensitivity has been reported | [ | |
| (3) Ototoxicity and nephrotoxicity can occur, particularly when used in large volumes or for an extended period of time | [ | |
|
| ||
| Mafenide acetate 0.5% cream (Sulfamylon) | (1) Inhibits human keratinocytes and fibroblasts in vitro | [ |
| (2) Mafenide suppresses PMN and lymphocyte activity | [ | |
| (3) The chance of a sulfa allergy is higher with mafenide acetate, and rashes may be seen in approximately | [ | |
| (4) Toxicity may increase in correlation with the duration of treatment and size of the treated area | [ | |
| (5) Painful upon application | [ | |
|
| ||
| Neomycin ointment | (1) Hypersensitivity reactions, particularly skin rashes, also occur more frequently with neomycin (occurring in 5%–8% of patients) | [ |
| (2) Ototoxicity and nephrotoxicity have been reported for large wounds | [ | |